Abstract 【Objective】 To analyze the correlation between neutrophil count/lymphocyte count (NLR), platelet count/lymphocyte count (PLR) and clinicopathological parameters in patients with breast cancer.【Methods】 Four hundred and thirty-three cases of breast cancer patients (breast cancer group), 631 cases of breast BIRADS class 1 (normal group) and 309 cases of breast BIRADS 2-3 (benign breast disease group) in our hospital from June to December 2018 were selected as the research objects. The age, neutrophil count, lymphocyte count, platelet count of each group were collected, and the clinicopathological data of breast cancer group were collected, including clinical stage, molecular typing, pathological grade, Ki67, lymph node metastasis and other indicators. NLR, platelet count and lymphocyte count were calculated to calculate PLR value. The NLR and PLR of normal group, benign breast disease group and breast cancer group were compared, and the relationship between NLR, PLR and clinicopathological parameters of breast cancer was analyzed.【Results】 There were significant differences in NLR among breast cancer group, benign breast disease group and normal group (P<0.05). There was significant difference in PLR among the three groups (P<0.05), but there was no significant difference between breast cancer and benign breast disease group, between breast cancer and normal group (P>0.05). The area under ROC curve (AUC) was 0.573, 95% CI was 0.54-0.606. NLR and PLR had no significant correlation with pathological grade, Ki67 and molecular typing of breast cancer (P>0.05). However, NLR was correlated with lymph node metastasis of breast cancer (P<0.05), and was positively correlated with NLR (rs=0.103, P=0.033). PLR was positively correlated with PLR (rs=0.188, P=0.00) and clinical stage (rs=0.135, P=0.005).【Conclusion】 The level of NLR and PLR can predict lymph node metastasis to a certain extent. PLR is positively correlated with clinical stage, suggesting that NLR and PLR have certain correlation with prognosis of breast cancer patients.
[1] Zuo TT, Zheng RS, Zeng HM,et al. Female breast cancer incidence and mortality in China, 2013[J].Thorac Cancer,2017,8(3):214-218. [2] Carioli G, Malvezzi M, Rodriguez T,et al.Trends and predictions to 2020 in breast cancer mortality in Europe[J].Breast,2017,36:89-95. [3] Coleman C. Early Detection and Screening for Breast Cancer[J].Semin Oncol Nurs,2017,33(2):141-155. [4] 黄育北,佟仲生,陈可欣,等.《中国女性乳腺癌筛查指南》解读(精简版)[J].中国肿瘤临床,2019,46(9):433-441. [5] 李美玲,张广美.NLR、MLR在卵巢肿瘤中的应用进展[J].中国生育健康杂志,2019,30(6):597-600. [6] 陈杰翔,廖大忠.NLR及PLR在膀胱尿路上皮癌中的表达及相关性分析[J].重庆医学,2019,48(22):3837-3844. [7] 郭静.NLR联合血清CA199、AFP水平检测对原发性肝癌的诊断价值[J].河南医学研究,2019,28(22):4157-4158. [8] 魏高辉,孟宪春,宋倩倩,等.血小板淋巴细胞比和中性粒细胞淋巴细胞比辅助筛查前列腺癌患者的作用研究[J].中国男科学杂志,2015,29(10):25-30. [9] Aboutorabi A, Kaviani A. Neutrophil-lymphocyte ratio in different stages of breast cancer[J].Acta Med Iran,2017,55(4):228-232. [10] 阳君,赵欣,苏丹柯,等.钼靶和超声及MRI对乳腺癌的诊断价值多中心研究及卫生经济学评价[J].放射学实践,2018,33(6):579-581. [11] 王浩峰,王耀辉,陆劲松.乳腺癌反映炎症状态外周血细胞间比值研究进展[J].中华肿瘤防治杂志,2019,26(8):598-602. [12] Nagini S. Breast cancer: current molecular therapeutic targets and new players[J].Anticancer Agents Med Chem,2017,17(2):152-163. [13] Karan D. Inflammasomes: emerging central players in cancer immunology and immunotherapy[J].Front Immunol,2018, 20(9):3028-3035. [14] Benevides L, da Fonseca DM,Donate PB,et al. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment[J].Cancer Res,2015,75(18): 3788-3799. [15] Silva RNF, Dallarmi LB, Araujo AKC, et al. Immunohistochemical analysis of neutrophils, interleukin17,matrix metalloproteinase9, and new formed vessels in oral squamous cell carcinoma[J].J Oral Pathol Med,2018,47(9):856-863. [16] Miyamoto R, Inagawa S, Sano N, et al. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients[J].Eur J Surg Oncol,2018,44(5):607-612. [17] Song W. Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis[J].PLoS One,2017,12( 6) : e0178762. [18] Huszno J, Kolosza Z. Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients[J].Oncol Lett,2019,18(6):6275-6283. [19] Ivars Rubio A, Yufera JC, de la Morena P, et al. Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables[J].Sci Rep,2019,9(1):16979. [20] 崔浩,吴瑶瑶,章龙珍.术前NLR、PLR与三阴性乳腺癌患者预后的相关性分析[J].现代肿瘤医学,2019,27(12):2087-2091.
2020, Vol. 37 
